Bringing A Different Science Into Solid Tumor Treatment
Depending on the regulatory jurisdiction, Nanobiotix’s radiation-activated cancer nanotechnology may be a drug or a device. But regardless of classification, it offers a physical solution to problems that chemistry and biology cannot solve.
You may also be interested in...
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.